Literature DB >> 10660394

Early identification of refractory epilepsy.

P Kwan1, M J Brodie.   

Abstract

BACKGROUND: More than 30 percent of patients with epilepsy have inadequate control of seizures with drug therapy, but why this happens and whether it can be predicted are unknown. We studied the response to antiepileptic drugs in patients with newly diagnosed epilepsy to identify factors associated with subsequent poor control of seizures.
METHODS: We prospectively studied 525 patients (age, 9 to 93 years) who were given a diagnosis, treated, and followed up at a single center between 1984 and 1997. Epilepsy was classified as idiopathic (with a presumed genetic basis), symptomatic (resulting from a structural abnormality), or cryptogenic (resulting from an unknown underlying cause). Patients were considered to be seizure-free if they had not had any seizures for at least one year.
RESULTS: Among the 525 patients, 333 (63 percent) remained seizure-free during antiepileptic-drug treatment or after treatment was stopped. The prevalence of persistent seizures was higher in patients with symptomatic or cryptogenic epilepsy than in those with idiopathic epilepsy (40 percent vs. 26 percent, P=0.004) and in patients who had had more than 20 seizures before starting treatment than in those who had had fewer (51 percent vs. 29 percent, P<0.001). The seizure-free rate was similar in patients who were treated with a single established drug (67 percent) and patients who were treated with a single new drug (69 percent). Among 470 previously untreated patients, 222 (47 percent) became seizure-free during treatment with their first antiepileptic drug and 67 (14 percent) became seizure-free during treatment with a second or third drug. In 12 patients (3 percent) epilepsy was controlled by treatment with two drugs. Among patients who had no response to the first drug, the percentage who subsequently became seizure-free was smaller (11 percent) when treatment failure was due to lack of efficacy than when it was due to intolerable side effects (41 percent) or an idiosyncratic reaction (55 percent).
CONCLUSIONS: Patients who have many seizures before therapy or who have an inadequate response to initial treatment with antiepileptic drugs are likely to have refractory epilepsy.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10660394     DOI: 10.1056/NEJM200002033420503

Source DB:  PubMed          Journal:  N Engl J Med        ISSN: 0028-4793            Impact factor:   91.245


  915 in total

Review 1.  Future prospects for the drug treatment of epilepsy.

Authors:  A Nicolson; J P Leach
Journal:  CNS Drugs       Date:  2001       Impact factor: 5.749

Review 2.  New antiepileptic drugs: comparative studies of efficacy and cognition.

Authors:  Steven L Weinstein; Joan Conry
Journal:  Curr Neurol Neurosci Rep       Date:  2002-03       Impact factor: 5.081

Review 3.  Recent developments in neurology.

Authors:  Samuel Wiebe; Michael W Nicolle
Journal:  BMJ       Date:  2002-03-16

4.  Pros and cons for the development of new antiepileptic drugs.

Authors:  Meir Bialer; Matthew C Walker; Josemir W Sander
Journal:  CNS Drugs       Date:  2002       Impact factor: 5.749

5.  Seizure treatment in transplant patients.

Authors:  Paul W Shepard; Erik K St Louis
Journal:  Curr Treat Options Neurol       Date:  2012-08       Impact factor: 3.598

6.  Hippocampal deep brain stimulation reduces glucose utilization in the healthy rat brain.

Authors:  Nathalie Van Den Berge; Vincent Keereman; Christian Vanhove; Bregt Van Nieuwenhuyse; Pieter van Mierlo; Robrecht Raedt; Kristl Vonck; Paul Boon; Roel Van Holen
Journal:  Mol Imaging Biol       Date:  2015-06       Impact factor: 3.488

Review 7.  Review of therapeutic options for adjuvant treatment of focal seizures in epilepsy: focus on lacosamide.

Authors:  Juan Luis Becerra; Joaquín Ojeda; Enrique Corredera; Jesús Ruiz Giménez
Journal:  CNS Drugs       Date:  2011-12-05       Impact factor: 5.749

8.  Addressing barriers to surgical evaluation for patients with epilepsy.

Authors:  Chloe E Hill; Jackie Raab; Delight Roberts; Timothy Lucas; John Pollard; Ammar Kheder; Brian Litt; Kathryn A Davis
Journal:  Epilepsy Behav       Date:  2018-07-19       Impact factor: 2.937

Review 9.  The effects of ABCC2 G1249A polymorphism on the risk of resistance to antiepileptic drugs: a meta-analysis of the literature.

Authors:  Pin Chen; Qing Yan; Haitao Xu; Ailin Lu; Peng Zhao
Journal:  Genet Test Mol Biomarkers       Date:  2013-12-10

10.  Properties of human brain sodium channel α-subunits expressed in HEK293 cells and their modulation by carbamazepine, phenytoin and lamotrigine.

Authors:  Xin Qiao; Guangchun Sun; Jeffrey J Clare; Taco R Werkman; Wytse J Wadman
Journal:  Br J Pharmacol       Date:  2014-02       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.